ReviewAntimicrobial agents and chemotherapy2013
Antifungal lock therapy.
Review in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Antimicrobial lock therapy in central-line associated bloodstream infections: a systematic review.Infection · 2015Pooled it
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- The fungal stronghold: biofilms in hemodialysis catheters, diagnostic pitfalls, and the challenge of catheter salvage.Frontiers in cellular and infection microbiology · 2026Review
- Amphibian-Derived Peptide Analog TB_KKG6K: A Powerful Drug Candidate AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Fungal biofilms in human health and disease.Nature reviews. Microbiology · 2025Review
- The Hidden Fortress: A Comprehensive Review of Fungal Biofilms with Emphasis onJournal of fungi (Basel, Switzerland) · 2025Review
- In Situ Aqueous Spice Extract-Based Antifungal Lock Strategy for Salvage of Foley's Catheter Biofouled withGels (Basel, Switzerland) · 2025Article
- Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Biofilm: The invisible culprit in catheter-induced candidemia.AIMS microbiology · 2023Review
- Antifungal lock therapy: an eternal promise or an effective alternative therapeutic approach?Letters in applied microbiology · 2022Review
- Use of Meropenem and Other Antimicrobial Lock Therapy in the Treatment of Catheter-Related Blood Stream Infections in Neonates: A Retrospective Study.Children (Basel, Switzerland) · 2022Article
- Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.Journal of fungi (Basel, Switzerland) · 2022Review
- Review
- Approaches for Mitigating Microbial Biofilm-Related Drug Resistance: A Focus on Micro- and Nanotechnologies.Molecules (Basel, Switzerland) · 2021Review
- Article
- Aspirin as an Antifungal-Lock Agent in Inhibition of Candidal Biofilm Formation in Surgical Catheters.Infection and drug resistance · 2021Article
- Combination Therapy to Treat Fungal Biofilm-Based Infections.International journal of molecular sciences · 2020Review
- Novel and potent antimicrobial effects of caspofungin on drug-resistant Candida and bacteria.Scientific reports · 2020Article
- Rational selection of antifungal drugs to propose a new formulation strategy to control Candida biofilm formation on venous catheters.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread use of intravascular devices, such as central venous and hemodialysis catheters, in the past 2 decades has paralleled the increasing incidence of catheter-related bloodstream infections (CR-BSIs). Candida albicans is the fourth leading cause of hospital-associated BSIs. The propensity of C. albicans to form biofilms on these catheters has made these infections difficult to treat due to multiple factors, including increased resistance to antifungal agents. Thus, curing CR-BSIs caused by Candida species usually requires catheter removal in addition to systemic antifungal therapy. Alternatively, antimicrobial lock therapy has received significant interest and shown promise as a strategy to treat CR-BSIs due to Candida species. The existing in vitro, animal, and patient data for treatment of Candida-related CR-BSIs are reviewed. The most promising antifungal lock therapy (AfLT) strategies include use of amphotericin, ethanol, or echinocandins. Clinical trials are needed to further define the safety and efficacy of AfLT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.